Literature DB >> 15113931

Induction of disease by a molecularly cloned highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimera is multigenic.

Reza Sadjadpour1, Theodore S Theodore, Tatsuhiko Igarashi, Olivia K Donau, Ronald J Plishka, Alicia Buckler-White, Malcolm A Martin.   

Abstract

One of three full-length infectious molecular clones of SHIV(DH12R), designated SHIV(DH12R-CL-7) and obtained from productively infected rhesus monkey peripheral blood mononuclear cells, directed rapid and irreversible loss of CD4+ T cells within 3 weeks of its inoculation into Indian rhesus monkeys. Induction of complete CD4+ T-cell depletion by SHIV(DH12R-CL-7) was found to be dependent on inoculum size. The acquisition of this pathogenic phenotype was accompanied by the introduction of 42 amino acid substitutions into multiple genes of parental nonpathogenic SHIV(DH12). Transfer of the entire SHIV(DH12R-CL-7) env gene into the genetic background of nonpathogenic SHIV(DH12) failed to confer the rapid CD4+ T-lymphocyte-depleting syndrome; similarly, the substitution of gag plus pol sequences from SIV(smE543) for analogous SIV(mac239) genes in SHIV(DH12R-CL-7) attenuated the pathogenic phenotype. Amino acid changes affecting multiple viral genes are necessary, but insufficient by themselves, to confer the prototypically rapid and irreversible CD4+ T-cell-depleting phenotype exhibited by molecularly cloned SHIV(DH12R-CL-7).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15113931      PMCID: PMC400343          DOI: 10.1128/jvi.78.10.5513-5519.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Construction and characterization of a stable full-length macrophage-tropic HIV type 1 molecular clone that directs the production of high titers of progeny virions.

Authors:  T S Theodore; G Englund; A Buckler-White; C E Buckler; M A Martin; K W Peden
Journal:  AIDS Res Hum Retroviruses       Date:  1996-02-10       Impact factor: 2.205

2.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

3.  Selective extraction of polyoma DNA from infected mouse cell cultures.

Authors:  B Hirt
Journal:  J Mol Biol       Date:  1967-06-14       Impact factor: 5.469

4.  Chimeric simian/human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques.

Authors:  S V Joag; Z Li; L Foresman; E B Stephens; L J Zhao; I Adany; D M Pinson; H M McClure; O Narayan
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Changes in growth properties on passage in tissue culture of viruses derived from infectious molecular clones of HIV-1LAI, HIV-1MAL, and HIV-1ELI.

Authors:  K Peden; M Emerman; L Montagnier
Journal:  Virology       Date:  1991-12       Impact factor: 3.616

6.  Amino acid deletions are introduced into the V2 region of gp120 during independent pathogenic simian immunodeficiency virus/HIV chimeric virus (SHIV) infections of rhesus monkeys generating variants that are macrophage tropic.

Authors:  Hiromi Imamichi; Tatsuhiko Igarashi; Tomozumi Imamichi; Olivia K Donau; Yasuyuki Endo; Yoshiaki Nishimura; Ronald L Willey; Anthony F Suffredini; H Clifford Lane; Malcolm A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

7.  Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo.

Authors:  R Shibata; M D Hoggan; C Broscius; G Englund; T S Theodore; A Buckler-White; L O Arthur; Z Israel; A Schultz; H C Lane
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

8.  An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1.

Authors:  R Collman; J W Balliet; S A Gregory; H Friedman; D L Kolson; N Nathanson; A Srinivasan
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

Authors:  K A Reimann; J T Li; R Veazey; M Halloran; I W Park; G B Karlsson; J Sodroski; N L Letvin
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

10.  Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles.

Authors:  Ronald L Willey; Russ Byrum; Michael Piatak; Young B Kim; Michael W Cho; Jeffrey L Rossio; Julian Bess; Tatsuhiko Igarashi; Yasuyuki Endo; Larry O Arthur; Jeffrey D Lifson; Malcolm A Martin
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

View more
  7 in total

1.  Identification of the peptide-binding motif recognized by the pigtail macaque class I MHC molecule Mane-A1*082:01 (Mane A*0301).

Authors:  Carrie Moore; John Sidney; A Michelle English; Amanda Wriston; Donald F Hunt; Jeffrey Shabanowitz; Scott Southwood; Kate Bradley; Bernard A P Lafont; Bianca R Mothé; Alessandro Sette
Journal:  Immunogenetics       Date:  2012-01-26       Impact factor: 2.846

2.  Recombination-mediated changes in coreceptor usage confer an augmented pathogenic phenotype in a nonhuman primate model of HIV-1-induced AIDS.

Authors:  Yoshiaki Nishimura; Masashi Shingai; Wendy R Lee; Reza Sadjadpour; Olivia K Donau; Ronald Willey; Jason M Brenchley; Ranjini Iyengar; Alicia Buckler-White; Tatsuhiko Igarashi; Malcolm A Martin
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

3.  Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains.

Authors:  Masashi Shingai; Olivia K Donau; Stephen D Schmidt; Rajeev Gautam; Ronald J Plishka; Alicia Buckler-White; Reza Sadjadpour; Wendy R Lee; Celia C LaBranche; David C Montefiori; John R Mascola; Yoshiaki Nishimura; Malcolm A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-05       Impact factor: 11.205

4.  CD8+ and CD20+ lymphocytes cooperate to control acute simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys: modulation by major histocompatibility complex genotype.

Authors:  Hanwen Mao; Bernard A P Lafont; Tatsuhiko Igarashi; Yoshiaki Nishimura; Charlie Brown; Vanessa Hirsch; Alicia Buckler-White; Reza Sadjadpour; Malcolm A Martin
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

5.  Some human immunodeficiency virus type 1 Vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo.

Authors:  Masashi Shingai; Takeshi Yoshida; Malcolm A Martin; Klaus Strebel
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

6.  Although macrophage-tropic simian/human immunodeficiency viruses can exhibit a range of pathogenic phenotypes, a majority of isolates induce no clinical disease in immunocompetent macaques.

Authors:  Tatsuhiko Igarashi; Olivia K Donau; Hiromi Imamichi; Yoshiaki Nishimura; Theodore S Theodore; Ranjini Iyengar; Christopher Erb; Alicia Buckler-White; Charles E Buckler; Malcolm A Martin
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

7.  Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.

Authors:  Masashi Shingai; Olivia K Donau; Ronald J Plishka; Alicia Buckler-White; John R Mascola; Gary J Nabel; Martha C Nason; David Montefiori; Brian Moldt; Pascal Poignard; Ron Diskin; Pamela J Bjorkman; Michael A Eckhaus; Florian Klein; Hugo Mouquet; Julio Cesar Cetrulo Lorenzi; Anna Gazumyan; Dennis R Burton; Michel C Nussenzweig; Malcolm A Martin; Yoshiaki Nishimura
Journal:  J Exp Med       Date:  2014-08-25       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.